Marine anticancer agents

Barreca, Marilia; Spanò, Virginia; Montalbano, Alessandra; Cueto, Mercedes; Díaz Marrero, Ana R.; Deniz, Irem; Erdoğan, Ayşegül; Lukić Bilela, Lada; Moulin, Corentin; Taffin-de-Givenchy, Elisabeth; Spriano, Filippo; Perale, Giuseppe; Mehiri, Mohamed; Rotter, Ana; Thomas, Olivier P.; Barraja, Paola; Gaudêncio, Susana P.; Bertoni, Francesco

doi:10.3390/md18120619

Back

Journal article

Marine anticancer agents : an overview with a particular focus on their chemical classes

Barreca, Marilia Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Italy - Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland
Spanò, Virginia Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Italy
Montalbano, Alessandra Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Italy
Cueto, Mercedes Instituto de Productos Naturales y Agrobiología (IPNA-CSIC), La Laguna, Tenerife, Spain
Díaz Marrero, Ana R. Instituto Universitario de Bio-Orgánica Antonio González (IUBO AG), Universidad de La Laguna (ULL), La Laguna, Tenerife, Spain
Deniz, Irem Department of Bioengineering, Faculty of Engineering, Manisa Celal Bayar University, Manisa, Turkey
Erdoğan, Ayşegül Research Center for Testing and Analysis (EGE MATAL), Ege University Application, İzmir, Turkey
Lukić Bilela, Lada Department of Biology, Faculty of Science, University of Sarajevo, Bosnia and Herzegovina
Moulin, Corentin Marine Natural Products Team, UMR 7272, Institut de Chimie de Nice, Université Côte d’Azur, CNRS, France
Taffin-de-Givenchy, Elisabeth Marine Natural Products Team, UMR 7272, Institut de Chimie de Nice, Université Côte d’Azur, CNRS, France
Spriano, Filippo Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland
Perale, Giuseppe Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland - Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Vienna, Austria
Mehiri, Mohamed Marine Natural Products Team, UMR 7272, Institut de Chimie de Nice, Université Côte d’Azur, CNRS, France
Rotter, Ana Marine Biology Station Piran, National Institute of Biology, Ljubljana, Slovenia
Thomas, Olivier P. Marine Biodiscovery Laboratory, School of Chemistry and Ryan Institute, National University of Ireland, Galway, Ireland
Barraja, Paola Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Italy
Gaudêncio, Susana P. UCIBIO—Applied Biomolecular Sciences Unit, Department of Chemistry, Blue Biotechnology & Biomedicine Lab, Faculty of Science and Technology, NOVA University of Lisbon, aparica, Portugal
Bertoni, Francesco Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland - Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland

04.12.2020

Published in:

Marine drugs. - 2020, vol. 18, no. 12, p. 28

English The marine environment is a rich source of biologically active molecules for the treatment of human diseases, especially cancer. The adaptation to unique environmental conditions led marine organisms to evolve different pathways than their terrestrial counterparts, thus producing unique chemicals with a broad diversity and complexity. So far, more than 36,000 compounds have been isolated from marine micro- and macro-organisms including but not limited to fungi, bacteria, microalgae, macroalgae, sponges, corals, mollusks and tunicates, with hundreds of new marine natural products (MNPs) being discovered every year. Marine-based pharmaceuticals have started to impact modern pharmacology and different anti- cancer drugs derived from marine compounds have been approved for clinical use, such as: cytarabine, vidarabine, nelarabine (prodrug of ara-G), fludarabine phosphate (pro-drug of ara-A), trabectedin, eribulin mesylate, brentuximab vedotin, polatuzumab vedotin, enfortumab vedotin, belantamab mafodotin, plitidepsin, and lurbinectedin. This review focuses on the bioactive molecules derived from the marine environment with anticancer activity, discussing their families, origin, structural features and therapeutic use.

Language